Stelac Advisory Services LLC Abb Vie Inc. Transaction History

Stelac Advisory Services LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1,073 - $1,231	8 Added 0.77%	1,051 $142,000
Q2 2022 Aug 10, 2022	BUY	$137.62 - $174.96 $143,537 - $182,483	1,043 New	1,043 $160,000
Q1 2022 May 10, 2022	SELL	$131.98 - $163.75 $137,259 - $170,300	-1,040 Closed	0 $0
Q4 2021 Jun 28, 2022	BUY	$107.43 - $135.93 $111,727 - $141,367	1,040 New	1,040 $141,000
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $169,176 - $192,040	-1,590 Closed	0 $0
Q2 2021 Jun 28, 2022	SELL	$105.21 - $117.21 $48,922 - $54,502	-465 Reduced 22.63%	1,590 $179,000
Q2 2021 Aug 09, 2021	BUY	$105.21 - $117.21 $47,870 - $53,330	455 Added 28.44%	2,055 $231,000
Q1 2021 Jun 28, 2022	SELL	$102.3 - $112.62 $79,794 - $87,843	-780 Reduced 32.77%	1,600 $173,000
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $66,085 - $72,752	-646 Reduced 21.35%	2,380 $258,000
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $243,562 - $328,835	3,026 New	3,026 $324,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $315B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Stelac Advisory Services LLC, based on Form 13F filings with the SEC.

Stay updated on Stelac Advisory Services LLC with notifications on news.